Surrozen Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Surrozen (Nasdaq: SRZN), a biotechnology company focused on Wnt pathway therapeutics for severe eye diseases, has granted inducement stock options to four new non-executive employees. The grants, approved on September 2, 2025, cover 45,710 shares of common stock at an exercise price of $12.32 per share.
The stock options were awarded under Surrozen's 2025 Equity Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The options vest over four years, with 25% vesting after the first year and the remainder vesting monthly thereafter, subject to continued employment.
Surrozen (Nasdaq: SRZN), una società biotecnologica che sviluppa terapie mirate alla via Wnt per gravi malattie oculari, ha assegnato opzioni su azioni come incentivo a quattro nuovi dipendenti non dirigenti. Le concessioni, approvate il 2 settembre 2025, riguardano 45.710 azioni ordinarie a un prezzo di esercizio di $12,32 per azione.
Le opzioni sono state concesse ai sensi del Piano di Incentivazione Azionaria 2025 di Surrozen, in conformità con la Regola di quotazione Nasdaq 5635(c)(4). Le opzioni maturano in un arco temporale di quattro anni: il 25% dopo il primo anno e il resto con maturazione mensile, subordinatamente al proseguimento del rapporto di lavoro.
Surrozen (Nasdaq: SRZN), una compañía biotecnológica centrada en terapias de la vía Wnt para enfermedades oculares graves, ha otorgado opciones sobre acciones como incentivo a cuatro nuevos empleados no ejecutivos. Las concesiones, aprobadas el 2 de septiembre de 2025, abarcan 45.710 acciones ordinarias a un precio de ejercicio de $12,32 por acción.
Las opciones se concedieron en virtud del Plan de Incentivos de Acciones 2025 de Surrozen, de conformidad con la Norma de cotización Nasdaq 5635(c)(4). Las opciones se consolidan durante cuatro años: el 25% tras el primer año y el resto en forma mensual, sujeto a la continuidad del empleo.
Surrozen (나스닥: SRZN)은 중증 안질환을 겨냥한 Wnt 경로 치료제에 주력하는 바이오텍 기업으로, 비임원 신입 직원 네 명에게 유인성 스톡옵션을 부여했습니다. 해당 부여는 2025년 9월 2일에 승인되었으며 45,710주의 보통주를 주당 $12.32의 행사가격으로 포함합니다.
이 옵션은 Surrozen의 2025년 주식 인센티브 플랜에 따라 나스닥 상장 규정 5635(c)(4)에 맞게 부여되었습니다. 옵션은 4년에 걸쳐 베스팅되며, 첫 해 이후 25%가 베스트되고 나머지는 매월 베스팅되며 계속 근무 조건이 적용됩니다.
Surrozen (Nasdaq: SRZN), une société de biotechnologie spécialisée dans les thérapeutiques ciblant la voie Wnt pour les maladies oculaires sévères, a accordé des options d'actions incitatives à quatre nouveaux employés non-dirigeants. Les attributions, approuvées le 2 septembre 2025, portent sur 45 710 actions ordinaires à un prix d'exercice de 12,32 $ par action.
Les options ont été attribuées dans le cadre du Plan d'incitation en actions 2025 de Surrozen, conformément à la règle de cotation Nasdaq 5635(c)(4). Elles acquièrent des droits sur une période de quatre ans : 25 % après la première année et le solde en acquisition mensuelle, sous réserve de la poursuite de l'emploi.
Surrozen (Nasdaq: SRZN), ein Biotechnologieunternehmen, das sich auf Wnt-Weg-Therapeutika für schwere Augenkrankheiten spezialisiert hat, hat Anreizaktienoptionen an vier neue nicht geschäftsführende Mitarbeiter gewährt. Die Zuteilungen wurden am 2. September 2025 genehmigt und umfassen 45.710 Aktien Stammaktien zu einem Ausübungspreis von $12,32 pro Aktie.
Die Optionen wurden im Rahmen des Surrozen 2025 Equity Inducement Plans gemäß der Nasdaq-Listing-Regel 5635(c)(4) gewährt. Die Optionen vesten über einen Zeitraum von vier Jahren: 25% nach dem ersten Jahr, der Rest monatlich, vorbehaltlich fortgesetzter Anstellung.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe eye diseases, today announced that on September 2, 2025, Surrozen granted inducement stock option awards covering an aggregate of 45,710 shares of Surrozen common stock to four recently hired non-executive employees as an inducement material to their acceptance of employment with Surrozen.
The awards were granted under Surrozen’s 2025 Equity Inducement Plan and provides for the granting of equity awards to new employees of Surrozen in accordance with Nasdaq Listing Rule 5635(c)(4). The grants were approved by the Compensation Committee of the Surrozen Board of Directors on September 2, 2025. Each grant provides for the purchase of shares of Surrozen common stock at a price of
The stock option awards vest over a four-year period, with 25 percent of the shares underlying the award vesting on the first anniversary of the award’s vesting commencement date based on the employee date of hire, and the remaining shares vesting ratably each month on the same date as the vesting commencement date (or if there is no corresponding day, on the last day of the month), subject to the employee’s continuous service as of each such vesting date. The awards were granted as an inducement material to the new employees entering into employment with Surrozen, in accordance with Nasdaq Listing Rule 5635(c)(4).
About Surrozen
Surrozen is a biotechnology company developing tissue-specific antibodies to selectively modulate the Wnt pathway, with a current focus on ophthalmology. Its proprietary technologies aim to harness the body’s biological repair mechanisms to treat severe diseases. For more information, visit www.surrozen.com.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally are accompanied by words such as “will,” “plan,” “intend,” “potential,” “expect,” “could,” or the negative of these words and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding Surrozen’s discovery, research and development activities, in particular its development plans for its product candidates (including anticipated clinical development plans and timelines, the availability of data, the potential for such product candidates to be used to treat human disease or address unmet needs in serious eye diseases, as well as the potential benefits and potential differentiation from existing therapies of such product candidates). These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management of Surrozen and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Surrozen. These forward-looking statements are subject to a number of risks and uncertainties, including the initiation, cost, timing, progress and results of research and development activities, preclinical and clinical trials with respect to its product candidates and potential future drug candidates; the Company’s ability to fund its preclinical and clinical trials and development efforts, whether with existing funds or through additional fundraising; Surrozen’s ability to identify, develop and commercialize drug candidates; Surrozen’s ability to successfully complete preclinical and clinical studies for its product candidates; the effects that arise from volatility in global economic, political, regulatory and market conditions; and all other factors discussed in Surrozen’s Annual Report on Form 10-K for the year ended December 31, 2024 filed, and Surrozen’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 filed with the Securities and Exchange Commission (“SEC”) under the heading “Risk Factors,” and other documents Surrozen has filed, or will file, with the SEC. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Surrozen presently does not know, or that Surrozen currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Surrozen’s expectations, plans, or forecasts of future events and views as of the date of this press release. Surrozen anticipates that subsequent events and developments will cause its assessments to change. However, while Surrozen may elect to update these forward-looking statements at some point in the future, Surrozen specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Surrozen’s assessments of any date after the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Investor/Media Contact:
Email: Investorinfo@surrozen.com
FAQ
What stock options did Surrozen (SRZN) grant to new employees in September 2025?
What is the vesting schedule for Surrozen's September 2025 employee stock options?
Why did Surrozen (SRZN) issue these stock options in September 2025?
What is Surrozen's (SRZN) main business focus?
